Meridian Bioscience(NASDAQ:VIVO) announced the earnings results for Fiscal Year 2016 and Q3. The results came in during Pre-market on Jul 28, 2016. Company reported revenue of $50.66M. Analysts estimated a revenue of $52.85M. Earnings per share were $0.21. Analysts had estimated an EPS of $0.22.
Meridian Bioscience (VIVO) shares turned negative on Thursdays trading session with the shares closing down -0.19 points or -0.98% at a volume of 1,43,887. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $19.4. The peak price level was also seen at $19.4 while the days lowest was $19.2. Finally the shares closed at $19.23. The 52-week high of the shares is $21.49 while the 52-week low is $16.6. According to the latest information available, the market cap of the company is $809 M.
Several Insider Transactions has been reported to the SEC. On May 2, 2016, Catherine Sazdanoff (director) purchased 7,700 shares at $19.20 per share price.Also, On Dec 10, 2015, Vecheslav A Elagin (EVP, Research & Development) sold 7,500 shares at $19.75 per share price.On Dec 2, 2015, Richard Eberly (EVP,Pres Meridian Life Science) sold 4,934 shares at $19.61 per share price, according to the Form-4 filing with the securities and exchange commission.
Meridian Bioscience Inc. (Meridian) is an integrated life science company. The Company is engaged in developing manufacturing selling and distribution of clinical diagnostic test kits for certain gastrointestinal viral respiratory and parasitic infectious diseases; the manufacture and distribution of bulk antigens antibodies polymerase chain reaction (PCR)/ quantitative polymerase chain reaction (qPCR) reagents nucleotides competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers and the contract development and manufacture of proteins and other biologicals under cyclic guanosine monophosphate (cGMP) conditions for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines. The Company operates in two segments: Diagnostics and Life Science.